EDAP TMS S.A.

NasdaqGM:EDAP Stock Report

Market Cap: US$152.9m

EDAP TMS Future Growth

Future criteria checks 1/6

EDAP TMS is forecast to grow earnings and revenue by 34.4% and 13.6% per annum respectively while EPS is expected to grow by 37.1% per annum.

Key information

34.4%

Earnings growth rate

37.05%

EPS growth rate

Medical Equipment earnings growth16.0%
Revenue growth rate13.6%
Future return on equityn/a
Analyst coverage

Low

Last updated08 May 2026

Recent future growth updates

Recent updates

Narrative Update • Apr 27

EDAP: Reaffirmed 2026 Revenue Guidance Will Support Refined Upside Thesis

Analysts have trimmed their price target on EDAP TMS by $4, citing updated assumptions around discount rates, revenue growth, and future P/E that refine their view of the company’s risk and earnings profile. Analyst Commentary Bullish analysts acknowledge the $4 trim to the price target as a recalibration to updated discount rate, revenue, and future P/E assumptions, rather than a change in their broader view of EDAP TMS.
Narrative Update • Apr 12

EDAP: Revised Outlook Will Rely On 2026 Revenue Guidance Execution

Analysts have lowered their price target on EDAP TMS to $10.00 from $14.00, citing updated assumptions on discount rates, revenue growth, profit margins, and future P/E expectations. Analyst Commentary Analysts lowering the price target to US$10.00 from US$14.00 reflects updated assumptions on discount rates, revenue growth, profit margins, and future P/E expectations rather than a single headline event.
Narrative Update • Mar 29

EDAP: Longer Term Revenue Outlook Will Support Future Upside

Analysts have adjusted their price target on EDAP TMS to $6.83. The change reflects updated assumptions for discount rate, revenue growth, profit margin, and future P/E that are now more closely aligned with their current modeling for the business.
Narrative Update • Mar 14

EDAP: 2026 Segment Guidance Will Limit Upside Versus Current Pricing

Analysts have adjusted their price target on EDAP TMS to reflect updated assumptions for revenue growth, profit margins, discount rate and future P/E. This has led to a revised valuation framework that investors should watch closely against the current share price in dollar terms.
Narrative Update • Feb 28

EDAP: 2026 Segment Guidance Will Constrain Future Share Price Upside

Analysts have lifted their EDAP TMS price target to reflect updated assumptions for a $2.50 fair value, a slightly higher discount rate, a shift from a 1.0% revenue decline to 20.8% growth expectations, a modestly stronger 13.40% profit margin outlook, and a lower forward P/E of about 11.6x. What's in the News EDAP TMS issued revenue guidance for 2026 for its HIFU business, with a range of $50.0 million to $54.0 million, or €43.0 million to €46.0 million.
Narrative Update • Feb 14

EDAP: Flat Revenue Outlook And Higher P/E Assumptions Will Limit Upside

Analysts have raised their $ fair value estimate for EDAP TMS from $1.50 to $2.50, citing updated assumptions that include a lower discount rate, a revenue growth outlook that is closer to flat, slightly higher profit margins, and a higher future P/E multiple. What's in the News Issued 2026 revenue guidance for the HIFU business in a range of $50.0 million to $54.0 million, or €43.0 million to €46.0 million (company guidance).
Analysis Article • Feb 03

EDAP TMS S.A. (NASDAQ:EDAP) Shares Fly 32% But Investors Aren't Buying For Growth

EDAP TMS S.A. ( NASDAQ:EDAP ) shares have continued their recent momentum with a 32% gain in the last month alone...
Narrative Update • Jan 31

EDAP: HIFU Guidance And FDA Clearance Will Support Future Upside

Analysts have adjusted their price target on EDAP TMS to US$25.18 from US$26.39, citing updated assumptions for the discount rate, profit margin and future P/E, which leave their fair value view broadly unchanged. What's in the News EDAP TMS issued 2026 revenue guidance, with HIFU business revenue expected in a range of US$50.0 million to US$54.0 million and non core Distribution and ESWL revenue in a range of US$22.0 million to US$26.0 million, also provided in euro terms as €43.0 million to €46.0 million and €19.0 million to €22.0 million respectively (company guidance).
Narrative Update • Jan 17

EDAP: Future Guidance And FDA Clearance Will Support Bullish Upside

Analysts now see higher upside for EDAP TMS, lifting their fair value estimate from about US$5.77 to roughly US$6.83 as they factor in slightly different assumptions around discount rate, revenue growth, profit margins and future P/E levels. What's in the News EDAP TMS issued 2026 revenue guidance, with HIFU business revenue expected in a range of US$50.0 million to US$54.0 million and non core Distribution and ESWL revenue in a range of US$22.0 million to US$26.0 million (Key Developments).
Analysis Article • Dec 20

EDAP TMS S.A.'s (NASDAQ:EDAP) Price Is Right But Growth Is Lacking After Shares Rocket 32%

EDAP TMS S.A. ( NASDAQ:EDAP ) shareholders would be excited to see that the share price has had a great month, posting...
Analysis Article • Dec 13

EDAP TMS (NASDAQ:EDAP) Has Debt But No Earnings; Should You Worry?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Narrative Update • Aug 29

CE Mark And Global Expansion Will Elevate HIFU Adoption

Despite a modest decline in consensus revenue growth forecasts, EDAP TMS’s sharply higher projected P/E multiple suggests increased investor optimism regarding future earnings quality or profitability, driving the analyst price target up from $5.75 to $14.00. What's in the News EDAP TMS raised its 2025 core HIFU business revenue growth guidance to 26%-34% year over year, up from the previous 16%-25% range.
Analysis Article • Aug 19

There Is A Reason EDAP TMS S.A.'s (NASDAQ:EDAP) Price Is Undemanding

EDAP TMS S.A.'s ( NASDAQ:EDAP ) price-to-sales (or "P/S") ratio of 0.8x might make it look like a strong buy right now...
Analysis Article • Jul 03

Is EDAP TMS (NASDAQ:EDAP) Using Debt Sensibly?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analysis Article • May 18

Improved Revenues Required Before EDAP TMS S.A. (NASDAQ:EDAP) Stock's 28% Jump Looks Justified

Those holding EDAP TMS S.A. ( NASDAQ:EDAP ) shares would be relieved that the share price has rebounded 28% in the last...
User avatar
New Narrative • Apr 08

CE Mark And Global Expansion Will Elevate HIFU Adoption

New approvals and strategic collaborations enhance EDAP TMS's market opportunities, potentially driving future revenue growth and improving margins.
Analysis Article • Apr 03

EDAP TMS S.A. (NASDAQ:EDAP) Stock's 27% Dive Might Signal An Opportunity But It Requires Some Scrutiny

EDAP TMS S.A. ( NASDAQ:EDAP ) shareholders that were waiting for something to happen have been dealt a blow with a 27...
Analysis Article • Mar 15

Is EDAP TMS (NASDAQ:EDAP) Using Too Much Debt?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
Analysis Article • Dec 25

Potential Upside For EDAP TMS S.A. (NASDAQ:EDAP) Not Without Risk

With a price-to-sales (or "P/S") ratio of 1.2x EDAP TMS S.A. ( NASDAQ:EDAP ) may be sending very bullish signals at the...
Analysis Article • Oct 24

Is EDAP TMS (NASDAQ:EDAP) Using Debt In A Risky Way?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
Analysis Article • Sep 07

Slammed 35% EDAP TMS S.A. (NASDAQ:EDAP) Screens Well Here But There Might Be A Catch

EDAP TMS S.A. ( NASDAQ:EDAP ) shareholders that were waiting for something to happen have been dealt a blow with a 35...
Analysis Article • Jul 24

Fewer Investors Than Expected Jumping On EDAP TMS S.A. (NASDAQ:EDAP)

EDAP TMS S.A.'s ( NASDAQ:EDAP ) price-to-sales (or "P/S") ratio of 2.6x might make it look like a buy right now...
Analysis Article • Mar 22

There's Reason For Concern Over EDAP TMS S.A.'s (NASDAQ:EDAP) Massive 28% Price Jump

Despite an already strong run, EDAP TMS S.A. ( NASDAQ:EDAP ) shares have been powering on, with a gain of 28% in the...
Analysis Article • Mar 03

Does EDAP TMS (NASDAQ:EDAP) Have A Healthy Balance Sheet?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article • Jan 19

It's A Story Of Risk Vs Reward With EDAP TMS S.A. (NASDAQ:EDAP)

With a median price-to-sales (or "P/S") ratio of close to 3.2x in the Medical Equipment industry in the United States...
Analysis Article • Aug 11

Investors Still Waiting For A Pull Back In EDAP TMS S.A. (NASDAQ:EDAP)

EDAP TMS S.A.'s ( NASDAQ:EDAP ) price-to-sales (or "P/S") ratio of 4.7x might make it look like a sell right now...
Analysis Article • Dec 19

Is There An Opportunity With EDAP TMS S.A.'s (NASDAQ:EDAP) 20% Undervaluation?

Does the December share price for EDAP TMS S.A. ( NASDAQ:EDAP ) reflect what it's really worth? Today, we will estimate...
Analysis Article • Nov 23

EDAP TMS' (NASDAQ:EDAP) Solid Profits Have Weak Fundamentals

Despite posting some strong earnings, the market for EDAP TMS S.A.'s ( NASDAQ:EDAP ) stock hasn't moved much. We did...
Seeking Alpha • Sep 22

EDAP TMS stock falls 7% aftermarket on proposed ADS offering

EDAP TMS (NASDAQ:EDAP) stock fell ~7% postmarket after the company said it commenced a public offering of its American depositary shares, each representing one ordinary share. There can be no assurance as to whether or when the proposed offering may be completed or the actual size or terms.
Seeking Alpha • Aug 24

EDAP TMS S.A. GAAP EPS of $0.06 beats by $0.09, revenue of $14.97M beats by $1.35M

EDAP TMS S.A. press release (NASDAQ:EDAP): Q2 GAAP EPS of $0.06 beats by $0.09. Revenue of $14.97M (+20.3% Y/Y) beats by $1.35M. 79% growth in HIFU revenues for the first half of 2022 compared to same period in 2021 Strong cash position of $48.5 million as of June 30, 2022 Company to host Focal One Expert User Panel event in New York City on Thursday, September 29.
Seeking Alpha • Aug 08

EDAP's Focal One Revenue Is Set To Accelerate

The placement of new Focal Ones got off to a good start this year and a filled-up pipeline is promising more, boosted by a big reimbursement improvement for Medicare. Reimbursement for Medicare patients' procedures almost doubled in July, significantly improving the economics for the Focal One. This should also speed up reimbursement from private payers and boost market acceptance. Most revenues still come from an exclusive distribution deal for the ExactVu with Exact Imaging, a clever move tiding the company over until reimbursement is improved. EDAP (EDAP) is a French medical device company that was known for its ESWL (extracorporeal shock wave lithotripsy) but it developed a HIFU (high-intensity focused ultrasound) robotic device, the Focal One, which is FDA approved for treating prostate cancer. HIFU works through soft tissue ablation through ultrasound, a minimally-invasive alternative for intermediate-risk prostate cancer and salvage treatment. The company got a bump in reimbursement, improving the attractiveness of the device, and there are still plenty of markets to pursue in the US and elsewhere. In the coming years, the Focal One could be approved for multiple additional indications while the company is also successfully selling the ExactVu from strategic partner Exact Imaging, which is actually responsible for most of its revenue. Growth There was, not surprisingly, a dip in the early quarters of the pandemic but apart from the last two quarters of 2021, growth has returned: Data by YCharts The most important growth vectors are: Placing more machines Increasing procedures Improving reimbursement Additional indications Placing more machines Q1 was a pretty good quarter for placing new machines, with four Focal One Robotic HIFU units sold, three of which were sold in the US at prestigious academic hospitals. Management argues that there is a growing pipeline, consisting of large academic hospitals but also increasingly community hospitals. Increasing the installed base also generates a tail of recurring revenues in the form of service contracts ($80K per year after year 1) and consumables (handpieces at $1800). They had a very successful presentation at the AUA, the American Urological Association, the largest annual gathering of neurologists worldwide where they showcased the Focal One and supported an accredited AUA course with hands-on training. Management argued they received additional interest as a result of the AUA. The company also sold nine ExactVu units (versus 5 in Q1/21), five of which were in the US, and one lithotripsy device for their legacy business (versus 6 in Q1/21). Increasing usage Management argued that the recently hired clinical sales managers had an immediate impact on usage within their existing customer base. They also engage in training programs for doctors to familiarize them with the Focal One. They didn't provide much detail on the CC about usage apart from noting that there was good usage momentum. Reimbursement The company does have a CPT (Current Procedural Terminology) code but management was disappointed when they were not bumped up to APC level 6, despite a unanimous conclusion from the advisory board. However, as expected, this all changed in July when the company finally achieved the APC level 6 code and this almost doubled the reimbursement from $4506 to $8711 (on average, there are slight variations determined by local wage levels) per procedure for Medicare patients. This not only increases the company's revenues from Medicare patients, it also furthers market adoption; from the company PR: The increase to APC level 6 has positive implications for patients beyond Medicare since many commercial payors have begun to cover focal HIFU for their members. Commercial payment and access policies are influenced by Medicare policy and reimbursement decisions. Additional indications Endometriosis BPH treatment Pancreatic cancer Liver cancer Breast cancer Endometriosis is furthest along as the company embarked on a (fairly small) P2 stage clinical trial which will end in September, with the first data expected before the end of the year. Other indications are further out. Financials From the 6-K: EDAP 6-K Results expressed in USD for Q2 will have some headwinds as the rate used in Q1 ($1.1177 euro per dollar) has come down considerably. Recurring revenues increased 17.5%, considerably less than the 44.4% rise in revenue from equipment. This isn't all that surprising as the newly sold devices do not earn any service revenue for the first year. Disaggregated revenue looks like this: EDAP 6-K It's quite remarkable that the distribution division is still by far the biggest revenue generator, this is the sales of the ExactVu, which is a device made by Exact Imaging, not EDAP. It's also the division that turns what would otherwise be an operating loss into an operating profit. That exclusive distribution deal is doing both companies wonders, no doubt about it. Margins Data by YCharts Since most of the sales come from the ExactVu, gross margins have suffered a bit since the start of 2021, but in the last two quarters, gross margins have recovered on economies of scale.
Analysis Article • Jul 19

Is EDAP TMS (NASDAQ:EDAP) Weighed On By Its Debt Load?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Earnings and Revenue Growth Forecasts

NasdaqGM:EDAP - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202889-22-28-232
12/31/202780-28-32-273
12/31/202675-34-39-353
3/31/202674-31-19-14N/A
12/31/202571-29-22-16N/A
9/30/202575-23-19-13N/A
6/30/202574-25-21-15N/A
3/31/202568-23-21-16N/A
12/31/202469-21-19-15N/A
9/30/202471-25-25-21N/A
6/30/202466-21-21-17N/A
3/31/202465-20-21-17N/A
12/31/202367-23-21-16N/A
9/30/202360-22-22-18N/A
6/30/202362-19-18-14N/A
3/31/202362-12-11-7N/A
12/31/202259-3-6-3N/A
9/30/202252346N/A
6/30/202253335N/A
3/31/202252024N/A
12/31/202150135N/A
9/30/202153057N/A
6/30/2021540N/AN/AN/A
3/31/2021520N/AN/AN/A
12/31/202051-202N/A
9/30/202045-4N/AN/AN/A
6/30/202044-2N/AN/AN/A
3/31/2020470N/AN/AN/A
12/31/2019502N/A4N/A
9/30/2019504N/AN/AN/A
6/30/2019502N/AN/AN/A
3/31/2019450N/AN/AN/A
12/31/2018450N/A0N/A
9/30/201842-2N/AN/AN/A
6/30/201841-2N/A0N/A
3/31/201845-3N/AN/AN/A
12/31/201743-1N/A-4N/A
9/30/201742-2N/AN/AN/A
6/30/2017420N/A-4N/A
3/31/2017384N/AN/AN/A
12/31/2016374N/A1N/A
9/30/20164111N/AN/AN/A
6/30/2016395N/A4N/A
3/31/2016402N/AN/AN/A
12/31/201535-2N/A1N/A
9/30/201530-11N/AN/AN/A
6/30/2015302N/A-2N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: EDAP is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: EDAP is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: EDAP is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: EDAP's revenue (13.6% per year) is forecast to grow faster than the US market (11.6% per year).

High Growth Revenue: EDAP's revenue (13.6% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if EDAP's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/13 13:20
End of Day Share Price 2026/05/13 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

EDAP TMS S.A. is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Andrew D'SilvaB. Riley Securities, Inc.
null nullCG Capital
Swayampakula RamakanthH.C. Wainwright & Co.